Ia Tykha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ia Tykha has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- I. P. Dunaieva
Kharkiv National Medical University
4 shared publications - Kateryna Misiura
SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
4 shared publications - Nonna Kravchun
Kharkiv National Medical University, Kharkiv, Ukraine; SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine»
4 shared publications - Ihor Marakhovskyi
SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
3 shared publications - Maryana Gorshunska
V.N. Karazin Kharkiv National University, Kharkiv, Ukraine
3 shared publications - Tetiana Tyzhnenko
SI “V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine”, Kharkiv, Ukraine
3 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 715-722
The potential role of the SLC22A1 rs628031 A>G polymorphism in the pathogenetic mechanisms of hormonal and metabolic response to antihyperglycemic therapy
Background. Metformin is widely used as a first-line antihyperglycemic therapy in patients with type 2 diabetes mellitus (T2DM); however, individual variability in treatment response remains an important clinical issue. Genetic variations in the solute carrier family 22 member 1 (SLC22A1) gene, encoding the organic cation transporter 1 (OCT1), may influence metformin pharmacokinetics and metabolic effects. The purpose of this study was to evaluate the potential role of the SLC22A1 rs628031 A>G (Met408Val) polymorphism in the pathogenetic mechanisms of hormonal and metabolic responses to antihyperglycemic therapy in patients with T2DM and obesity. Materials and methods. The study included 61 patients with T2DM aged 28–80 years (35 men and 26 women) with metabolic syndrome and obesity (body mass index ≥ 30 kg/m2). All patients received oral antihyperglycemic therapy, including metformin, sulfonylureas, or their combinations. According to the antihyperglycemic therapy received, the patients were retrospectively divided into two groups: those receiving metformin-based therapy and those treated with other glucose-lowering agents (sulfonylureas or their combinations without metformin). Clinical, anthropometric, biochemical, hormonal, and metabolic parameters were assessed, including carbohydrate and lipid metabolism indices, liver function markers, adipokine profile, and oxidative stress parameters. Genotyping of the SLC22A1 rs628031 A>G polymorphism was performed using polymerase chain reaction and restriction fragment length polymorphism analysis with MscI restriction enzyme. Results. Metformin-based therapy was associated with favorable changes in glycemic control, lipid profile, adipokine status, and oxidative stress markers in patients with T2DM and obesity. Carriers of the AG genotype of the SLC22A1 rs628031 polymorphism receiving metformin demonstrated significantly lower levels of low-density lipoprotein cholesterol, total cholesterol, omentin, osteoprotegerin, alanine aminotransferase, and aspartate aminotransferase compared with other genotype groups. At the same time, AG genotype carriers showed higher omentin and osteoprotegerin concentrations compared with AA genotype carriers, suggesting genotype-dependent modulation of metformin-associated metabolic effects. Conclusions. The obtained results indicate that the SLC22A1 rs628031 A>G polymorphism may contribute to variability in hormonal and metabolic responses to metformin therapy in patients with T2DM and obesity. Genetic differences in OCT1 function may influence lipid metabolism, adipokine regulation, liver homeostasis, and potentially bone-related metabolic processes. Assessment of SLC22A1 genetic variants may contribute to the development of personalized approaches for optimizing antihyperglycemic therapy and improving metabolic outcomes in patients with diabetes and metabolic disorders.
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 715-722
Open AccessThe potential role of the SLC22A1 rs628031 A>G polymorphism in the pathogenetic mechanisms of hormonal and metabolic response to antihyperglycemic therapy
Background. Metformin is widely used as a first-line antihyperglycemic therapy in patients with type 2 diabetes mellitus (T2DM); however, individual variability in treatment response remains an important clinical issue. Genetic variations in the solute carrier family 22 member 1 (SLC22A1) gene, encoding the organic cation transporter 1 (OCT1), may influence metformin pharmacokinetics and metabolic effects. The purpose of this study was to evaluate the potential role of the SLC22A1 rs628031 A>G (Met408Val) polymorphism in the pathogenetic mechanisms of hormonal and metabolic responses to antihyperglycemic therapy in patients with T2DM and obesity. Materials and methods. The study included 61 patients with T2DM aged 28–80 years (35 men and 26 women) with metabolic syndrome and obesity (body mass index ≥ 30 kg/m2). All patients received oral antihyperglycemic therapy, including metformin, sulfonylureas, or their combinations. According to the antihyperglycemic therapy received, the patients were retrospectively divided into two groups: those receiving metformin-based therapy and those treated with other glucose-lowering agents (sulfonylureas or their combinations without metformin). Clinical, anthropometric, biochemical, hormonal, and metabolic parameters were assessed, including carbohydrate and lipid metabolism indices, liver function markers, adipokine profile, and oxidative stress parameters. Genotyping of the SLC22A1 rs628031 A>G polymorphism was performed using polymerase chain reaction and restriction fragment length polymorphism analysis with MscI restriction enzyme. Results. Metformin-based therapy was associated with favorable changes in glycemic control, lipid profile, adipokine status, and oxidative stress markers in patients with T2DM and obesity. Carriers of the AG genotype of the SLC22A1 rs628031 polymorphism receiving metformin demonstrated significantly lower levels of low-density lipoprotein cholesterol, total cholesterol, omentin, osteoprotegerin, alanine aminotransferase, and aspartate aminotransferase compared with other genotype groups. At the same time, AG genotype carriers showed higher omentin and osteoprotegerin concentrations compared with AA genotype carriers, suggesting genotype-dependent modulation of metformin-associated metabolic effects. Conclusions. The obtained results indicate that the SLC22A1 rs628031 A>G polymorphism may contribute to variability in hormonal and metabolic responses to metformin therapy in patients with T2DM and obesity. Genetic differences in OCT1 function may influence lipid metabolism, adipokine regulation, liver homeostasis, and potentially bone-related metabolic processes. Assessment of SLC22A1 genetic variants may contribute to the development of personalized approaches for optimizing antihyperglycemic therapy and improving metabolic outcomes in patients with diabetes and metabolic disorders.
- Open Access
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 599-604
Plasma atherogenic index as a non-invasive criterion for the diagnosis of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
Background. Identification of risk factors and detection of target organs in the early stages of the formation of cardiovascular diseases, liver and kidney diseases and other complications with the correction of identified disorders is an integral part of the successful reduction of morbidity and mortality among the population. Diabetes mellitus (DM) is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. The purpose of the study was to determine the presence and nature of the relationship of a new indirect index with the presence (or absence) of metabolically associated steatotic fatty liver disease (MASLD) in patients with T2DM, to determine the contribution of the atherogenic index of plasma (AIP) to the risk of developing liver disease and to characterize its diagnostic value using logistic regression and ROC analysis. Materials and methods. Sixty patients with T2DM were examined (33/27 men/women; age 53.00 ± 1.20 years; disease duration 13.36 ± 3.49 years), of them 24 participants with MASLD and 36 without it. The diagnosis of MASLD was established on the basis of clinical analysis of the disease, lipid and carbohydrate metabolism indicators, aspartate aminotransferase and alanine aminotransferase activity and ultrasound examination of the liver. Results. A significant and statistically significant relationship was found between the AIP and the presence of metabolically associated fatty liver disease. A distinct and significant correlation was established between the AIP and glycemia, as well as some indicators of oxidative stress (in particular, the index of free fatty acids and OXY levels) and the level of lipocalin, an adipokine. A diagnostic model was developed to identify risk groups for the development of MASLD in patients with T2DM based on the AIP. Conclusions. A diagnostic model was developed to form risk groups for MASLD among patients with T2DM using logistic regression and ROC analysis. The diagnostic criterion is a new non-invasive indicator — the AIP, the threshold value of the predictor is defined as 0.60.
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 599-604
Open AccessPlasma atherogenic index as a non-invasive criterion for the diagnosis of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
Background. Identification of risk factors and detection of target organs in the early stages of the formation of cardiovascular diseases, liver and kidney diseases and other complications with the correction of identified disorders is an integral part of the successful reduction of morbidity and mortality among the population. Diabetes mellitus (DM) is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. The purpose of the study was to determine the presence and nature of the relationship of a new indirect index with the presence (or absence) of metabolically associated steatotic fatty liver disease (MASLD) in patients with T2DM, to determine the contribution of the atherogenic index of plasma (AIP) to the risk of developing liver disease and to characterize its diagnostic value using logistic regression and ROC analysis. Materials and methods. Sixty patients with T2DM were examined (33/27 men/women; age 53.00 ± 1.20 years; disease duration 13.36 ± 3.49 years), of them 24 participants with MASLD and 36 without it. The diagnosis of MASLD was established on the basis of clinical analysis of the disease, lipid and carbohydrate metabolism indicators, aspartate aminotransferase and alanine aminotransferase activity and ultrasound examination of the liver. Results. A significant and statistically significant relationship was found between the AIP and the presence of metabolically associated fatty liver disease. A distinct and significant correlation was established between the AIP and glycemia, as well as some indicators of oxidative stress (in particular, the index of free fatty acids and OXY levels) and the level of lipocalin, an adipokine. A diagnostic model was developed to identify risk groups for the development of MASLD in patients with T2DM based on the AIP. Conclusions. A diagnostic model was developed to form risk groups for MASLD among patients with T2DM using logistic regression and ROC analysis. The diagnostic criterion is a new non-invasive indicator — the AIP, the threshold value of the predictor is defined as 0.60.
- Open Access
- 15 September 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (3) , 15-26
NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A MARKER OF RENAL DAMAGE IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
Introduction. The combination of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) is associated with an increased risk of target organ damage, particularly renal injury, which necessitates the search for early biomarkers of subclinical damage. Neutrophil gelatinase-associated lipocalin (NGAL) is considered a promising marker of early nephropathic and cardiometabolic changes; however, its relationships with clinical and metabolic parameters in AH, especially when combined with T2DM, remain insufficiently studied. Aim. To investigate clinical, laboratory, immunological, biochemical, and hemodynamic factors and to determine their association with NGAL levels in patients with arterial hypertension with and without type 2 diabetes mellitus. Materials and Methods. The study included 136 patients with AH, divided into two groups: the first group comprised patients with isolated AH (n=64), and the second group comprised patients with AH combined with T2DM (n=72). The control group consisted of 20 apparently healthy individuals. All participants underwent clinical, biochemical, immunological, and instrumental examinations, including assessment of lipid profile, HbA1c, insulin, cystatin C, leptin, NT-proBNP, and NGAL by ELISA; evaluation of lymphocyte subpopulations, renal function indices, and echocardiographic parameters. Statistical analysis was performed using correlation and stepwise multiple regression. Results. Patients with combined AH and T2DM demonstrated a more unfavourable metabolic profile, with increased BMI, total cholesterol, triglycerides, and atherogenic coefficient, as well as activation of the cellular immune response and more pronounced myocardial remodeling. NGAL levels did not differ significantly between the groups (p>0.05). Stratification by the median NGAL level showed a significant increase in leptin (p=0.011) and a decrease in insulin (p=0.009) in patients with higher NGAL values. According to stepwise regression analysis, independent predictors of NGAL in patients with AH were HbA1c, urea level, insulin level, and diastolic blood pressure (R²=0.31; p<0.0139). In patients with AH + T2DM, the model demonstrated greater explanatory power (R²=0.37; p<0.035) and included metabolic, immunological, and echocardiographic parameters. Conclusions. NGAL levels in patients with arterial hypertension are shaped by a complex set of metabolic, immunological, and hemodynamic factors. In the presence of concomitant type 2 diabetes mellitus, the spectrum of determinants expands to include indicators of myocardial remodeling and immune activation. NGAL is associated with disturbances in adipokine regulation and insulin homeostasis and may be considered an integral biomarker for early subclinical target-organ damage and for cardiometabolic risk stratification.
- 15 September 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (3) , 15-26
Open AccessNEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A MARKER OF RENAL DAMAGE IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
Introduction. The combination of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) is associated with an increased risk of target organ damage, particularly renal injury, which necessitates the search for early biomarkers of subclinical damage. Neutrophil gelatinase-associated lipocalin (NGAL) is considered a promising marker of early nephropathic and cardiometabolic changes; however, its relationships with clinical and metabolic parameters in AH, especially when combined with T2DM, remain insufficiently studied. Aim. To investigate clinical, laboratory, immunological, biochemical, and hemodynamic factors and to determine their association with NGAL levels in patients with arterial hypertension with and without type 2 diabetes mellitus. Materials and Methods. The study included 136 patients with AH, divided into two groups: the first group comprised patients with isolated AH (n=64), and the second group comprised patients with AH combined with T2DM (n=72). The control group consisted of 20 apparently healthy individuals. All participants underwent clinical, biochemical, immunological, and instrumental examinations, including assessment of lipid profile, HbA1c, insulin, cystatin C, leptin, NT-proBNP, and NGAL by ELISA; evaluation of lymphocyte subpopulations, renal function indices, and echocardiographic parameters. Statistical analysis was performed using correlation and stepwise multiple regression. Results. Patients with combined AH and T2DM demonstrated a more unfavourable metabolic profile, with increased BMI, total cholesterol, triglycerides, and atherogenic coefficient, as well as activation of the cellular immune response and more pronounced myocardial remodeling. NGAL levels did not differ significantly between the groups (p>0.05). Stratification by the median NGAL level showed a significant increase in leptin (p=0.011) and a decrease in insulin (p=0.009) in patients with higher NGAL values. According to stepwise regression analysis, independent predictors of NGAL in patients with AH were HbA1c, urea level, insulin level, and diastolic blood pressure (R²=0.31; p<0.0139). In patients with AH + T2DM, the model demonstrated greater explanatory power (R²=0.37; p<0.035) and included metabolic, immunological, and echocardiographic parameters. Conclusions. NGAL levels in patients with arterial hypertension are shaped by a complex set of metabolic, immunological, and hemodynamic factors. In the presence of concomitant type 2 diabetes mellitus, the spectrum of determinants expands to include indicators of myocardial remodeling and immune activation. NGAL is associated with disturbances in adipokine regulation and insulin homeostasis and may be considered an integral biomarker for early subclinical target-organ damage and for cardiometabolic risk stratification.
- 10 June 2026
- Published by Ukrainian Diabetology Association in Diabetes Obesity Metabolic Syndrome
CARDIOMETABOLIC DETERMINANTS OF ELEVATED NT-proBNP CONCENTRATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION
The combination of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) is associated with a high risk of cardiac remodeling, left ventricular diastolic dysfunction, and the development of heart failure. The N-terminal fragment of the prohormone of brain natriuretic peptide (NT-proBNP) is considered a sensitive biomarker of myocardial stress, increased left ventricular filling pressure, and early structural and functional cardiac changes. However, the cardiometabolic factors determining elevated NT-proBNP concentrations in patients with combined AH and T2DM remain insufficiently studied. Aim To determine the cardiometabolic determinants of elevated NT-proBNP concentrations in patients with type 2 diabetes mellitus and arterial hypertension. Materials and Methods The study included 136 patients with AH, divided into two groups: the first group comprised patients with isolated AH (n = 64), and the second group comprised patients with AH combined with T2DM (n = 72). The control group consisted of 20 apparently healthy individuals. All participants underwent a comprehensive clinical, laboratory, and instrumental examination, including assessment of lipid profile parameters, HbA1c, insulin, leptin, cystatin C (Cys C), NGAL, and NT-proBNP by enzyme-linked immunosorbent assay; evaluation of lymphocyte subpopulations; assessment of renal function parameters; and echocardiographic evaluation. To determine the factors associated with elevated NT-proBNP concentrations, univariate and multivariate logistic regression analyses were performed, with odds ratios and 95% confidence intervals calculated, and the prognostic performance of the models assessed using ROC analysis. Results Patients with combined AH and T2DM had a more unfavourable cardiometabolic profile than patients with isolated AH. This was manifested by higher body mass index, total cholesterol, triglycerides, and atherogenic coefficient, increased leptin levels, activation of the cellular immune system, and more pronounced structural and functional cardiac remodelling. In the AH + T2DM group, increased left ventricular myocardial mass, left ventricular mass index, cardiac chamber dimensions, reduced left ventricular ejection fraction, and impaired diastolic function parameters were observed. NT-proBNP concentrations in patients with AH + T2DM tended to be higher than in the isolated AH group; however, the between-group difference did not reach statistical significance (p = 0.0791). According to multivariate logistic regression analysis, in patients with isolated AH, independent predictors of elevated NT-proBNP concentrations were aortic size and left ventricular myocardial mass; the model’s prognostic performance was good (AUC = 0.868). In patients with combined AH and T2DM, the independent cardiometabolic determinants of elevated NT-proBNP concentrations were isovolumic relaxation time (IVRT), early diastolic filling velocity (VE), left ventricular mass index indexed to height, insulin concentration, and systolic blood pressure. The multivariate model in the AH + T2DM group also demonstrated good prognostic performance (AUC=0.803). Conclusion Elevated NT-proBNP concentrations in patients with AH and T2DM are formed under the influence of a complex of hemodynamic, metabolic, and structural-functional factors. In isolated AH, cardiac remodelling parameters are of primary importance, whereas in combined AH and T2DM, the spectrum of determinants expands to include indicators of diastolic dysfunction, left ventricular hypertrophy, insulin homeostasis, and systolic blood pressure. NT-proBNP may be considered an integral biomarker of early cardiac remodelling, subclinical diastolic dysfunction, and cardiometabolic risk stratification in patients with comorbid AH and T2DM.
- 10 June 2026
- Published by Ukrainian Diabetology Association in Diabetes Obesity Metabolic Syndrome
CARDIOMETABOLIC DETERMINANTS OF ELEVATED NT-proBNP CONCENTRATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION
The combination of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) is associated with a high risk of cardiac remodeling, left ventricular diastolic dysfunction, and the development of heart failure. The N-terminal fragment of the prohormone of brain natriuretic peptide (NT-proBNP) is considered a sensitive biomarker of myocardial stress, increased left ventricular filling pressure, and early structural and functional cardiac changes. However, the cardiometabolic factors determining elevated NT-proBNP concentrations in patients with combined AH and T2DM remain insufficiently studied. Aim To determine the cardiometabolic determinants of elevated NT-proBNP concentrations in patients with type 2 diabetes mellitus and arterial hypertension. Materials and Methods The study included 136 patients with AH, divided into two groups: the first group comprised patients with isolated AH (n = 64), and the second group comprised patients with AH combined with T2DM (n = 72). The control group consisted of 20 apparently healthy individuals. All participants underwent a comprehensive clinical, laboratory, and instrumental examination, including assessment of lipid profile parameters, HbA1c, insulin, leptin, cystatin C (Cys C), NGAL, and NT-proBNP by enzyme-linked immunosorbent assay; evaluation of lymphocyte subpopulations; assessment of renal function parameters; and echocardiographic evaluation. To determine the factors associated with elevated NT-proBNP concentrations, univariate and multivariate logistic regression analyses were performed, with odds ratios and 95% confidence intervals calculated, and the prognostic performance of the models assessed using ROC analysis. Results Patients with combined AH and T2DM had a more unfavourable cardiometabolic profile than patients with isolated AH. This was manifested by higher body mass index, total cholesterol, triglycerides, and atherogenic coefficient, increased leptin levels, activation of the cellular immune system, and more pronounced structural and functional cardiac remodelling. In the AH + T2DM group, increased left ventricular myocardial mass, left ventricular mass index, cardiac chamber dimensions, reduced left ventricular ejection fraction, and impaired diastolic function parameters were observed. NT-proBNP concentrations in patients with AH + T2DM tended to be higher than in the isolated AH group; however, the between-group difference did not reach statistical significance (p = 0.0791). According to multivariate logistic regression analysis, in patients with isolated AH, independent predictors of elevated NT-proBNP concentrations were aortic size and left ventricular myocardial mass; the model’s prognostic performance was good (AUC = 0.868). In patients with combined AH and T2DM, the independent cardiometabolic determinants of elevated NT-proBNP concentrations were isovolumic relaxation time (IVRT), early diastolic filling velocity (VE), left ventricular mass index indexed to height, insulin concentration, and systolic blood pressure. The multivariate model in the AH + T2DM group also demonstrated good prognostic performance (AUC=0.803). Conclusion Elevated NT-proBNP concentrations in patients with AH and T2DM are formed under the influence of a complex of hemodynamic, metabolic, and structural-functional factors. In isolated AH, cardiac remodelling parameters are of primary importance, whereas in combined AH and T2DM, the spectrum of determinants expands to include indicators of diastolic dysfunction, left ventricular hypertrophy, insulin homeostasis, and systolic blood pressure. NT-proBNP may be considered an integral biomarker of early cardiac remodelling, subclinical diastolic dysfunction, and cardiometabolic risk stratification in patients with comorbid AH and T2DM.
- Open Access
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 799-806
Adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 as one of the factors in the pharmacogenetics of type 2 diabetes mellitus
Background. Diabetes mellitus is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. Numerous risk factors for the development of type 2 diabetes have been identified, the most important of which is the pathogenetic contribution of visceral obesity. Adipose tissue is now understood to be an active endocrine organ, secreting various hormones and cytokines that regulate metabolism and inflammation. The ADIPOQ gene located on chromosome 3q27, a region that recent scans of the entire human genome have suggested as a “type 2 diabetes susceptibility locus”, encodes the hormone adiponectin, which is derived from adipose tissue. The purpose of the study is to clarify the role of the adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 in the mechanisms of pharmacogenetic response in patients with obesity and type 2 diabetes, taking into account the assessment of its impact on the course and effectiveness of therapy. Materials and methods. Sixty-one people were selected for analysis. All patients received oral hypoglycemic drugs: sulfonamides, biguanides or their combination before hospitalization in the clinic. A comparative analysis of a number of biochemical parameters was conducted in the groups that took or did not take metformin as the main sugar-lowering drug, considering the single nucleotide polymorphism of the adiponectin gene. Results. The results indicate that the aforementioned drug has antioxidant properties, a certain hepatoprotective effect (a significant decrease in aspartate and alanine aminotransferase in G allele carriers who received the drug); also, the ability to improve the lipid profile, including in G allele carriers, has been statistically proven, that is, it has the potential to reduce the risk of developing cardiovascular complications, which is the main cause of death in patients. Conclusions. Genetic testing can be used to divide patients with type 2 diabetes and obesity into specific clusters and/or endophenotypes. Advances in the field of pharmacogenomics will allow clinicians to select personalized drug therapy regimens in order to increase its effectiveness and reduce the risk of developing adverse events.
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 799-806
Open AccessAdiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 as one of the factors in the pharmacogenetics of type 2 diabetes mellitus
Background. Diabetes mellitus is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. Numerous risk factors for the development of type 2 diabetes have been identified, the most important of which is the pathogenetic contribution of visceral obesity. Adipose tissue is now understood to be an active endocrine organ, secreting various hormones and cytokines that regulate metabolism and inflammation. The ADIPOQ gene located on chromosome 3q27, a region that recent scans of the entire human genome have suggested as a “type 2 diabetes susceptibility locus”, encodes the hormone adiponectin, which is derived from adipose tissue. The purpose of the study is to clarify the role of the adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 in the mechanisms of pharmacogenetic response in patients with obesity and type 2 diabetes, taking into account the assessment of its impact on the course and effectiveness of therapy. Materials and methods. Sixty-one people were selected for analysis. All patients received oral hypoglycemic drugs: sulfonamides, biguanides or their combination before hospitalization in the clinic. A comparative analysis of a number of biochemical parameters was conducted in the groups that took or did not take metformin as the main sugar-lowering drug, considering the single nucleotide polymorphism of the adiponectin gene. Results. The results indicate that the aforementioned drug has antioxidant properties, a certain hepatoprotective effect (a significant decrease in aspartate and alanine aminotransferase in G allele carriers who received the drug); also, the ability to improve the lipid profile, including in G allele carriers, has been statistically proven, that is, it has the potential to reduce the risk of developing cardiovascular complications, which is the main cause of death in patients. Conclusions. Genetic testing can be used to divide patients with type 2 diabetes and obesity into specific clusters and/or endophenotypes. Advances in the field of pharmacogenomics will allow clinicians to select personalized drug therapy regimens in order to increase its effectiveness and reduce the risk of developing adverse events.
- Open Access
- 15 March 2025
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 82 (1) , 89-94
ДОСВІД ВИКОРИСТАННЯ ПРЕПАРАТУ «ОЛІДЕТРИМ Д3 ФОРТЕ 10 000» В КОМПЛЕКСНІЙ ТЕРАПІЇ ПАЦІЄНТІВ З МЕТАБОЛІЧНИМ СИНДРОМОМ ТА НАЯВНИМ ДЕФІЦИТОМ ВІТАМІНУ D3
Мета дослідження: оцінка ефективності препарату «Олідетрим Д3 Форте 10 000» у комплексній терапії пацієнтів з метаболічним синдромом та дефіцитом вітаміну D. Проведено аналіз впливу препарату на показники вуглеводного та ліпідного обміну, масу тіла, артеріальний тиск та серцево-судинний ризик. Методи дослідження: у дослідженні взяли участь 70 пацієнтів, які були розподілені на дві групи: основну (приймали «Олідетрим Д3 Форте 10 000») та контрольну (приймали інші препарати вітаміну D). Проводився динамічний моніторинг рівня 25(ОН)D, паратгормону, індексу маси тіла, вуглеводного та ліпідного обмінів. Результати: пацієнти основної групи демонстрували значне покращення рівня 25(ОН)D у сироватці крові, зниження паратгормону, маси тіла, артеріального тиску, а також покращення показників глюкози натще, глікованого гемоглобіну та холестерину. Висновки: Препарат «Олідетрим Д3 Форте 10 000» є ефективним і безпечним у нормалізації вітаміну D, що сприяє зниженню метаболічного та серцево-судинного ризику.
- 15 March 2025
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 82 (1) , 89-94
Open AccessДОСВІД ВИКОРИСТАННЯ ПРЕПАРАТУ «ОЛІДЕТРИМ Д3 ФОРТЕ 10 000» В КОМПЛЕКСНІЙ ТЕРАПІЇ ПАЦІЄНТІВ З МЕТАБОЛІЧНИМ СИНДРОМОМ ТА НАЯВНИМ ДЕФІЦИТОМ ВІТАМІНУ D3
Мета дослідження: оцінка ефективності препарату «Олідетрим Д3 Форте 10 000» у комплексній терапії пацієнтів з метаболічним синдромом та дефіцитом вітаміну D. Проведено аналіз впливу препарату на показники вуглеводного та ліпідного обміну, масу тіла, артеріальний тиск та серцево-судинний ризик. Методи дослідження: у дослідженні взяли участь 70 пацієнтів, які були розподілені на дві групи: основну (приймали «Олідетрим Д3 Форте 10 000») та контрольну (приймали інші препарати вітаміну D). Проводився динамічний моніторинг рівня 25(ОН)D, паратгормону, індексу маси тіла, вуглеводного та ліпідного обмінів. Результати: пацієнти основної групи демонстрували значне покращення рівня 25(ОН)D у сироватці крові, зниження паратгормону, маси тіла, артеріального тиску, а також покращення показників глюкози натще, глікованого гемоглобіну та холестерину. Висновки: Препарат «Олідетрим Д3 Форте 10 000» є ефективним і безпечним у нормалізації вітаміну D, що сприяє зниженню метаболічного та серцево-судинного ризику.
- Open Access
- 14 March 2024
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 81 (1) , 35-40
ЗМІНИ В ТИРЕОЇДНОМУ ГОРМОНАЛЬНОМУ СТАТУСІ ПОРАНЕНИХ В ЗАЛЕЖНОСТІ ВІД ОБ’ЄМУ РАНОВОГО УШКОДЖЕННЯ
Рановий процес – це складний комплекс місцевих та загальних реакцій організму, що розвиваються у відповідь на пошкодження тканин. Внаслідок розпочатої у лютому 2022 року збройної агресії росії проти України значно зросла кількість осіб, які отримали бойову травму. Швидкість загоєння цих травм та перебіг ранового процесу залежать від багатьох факторів, одним з яких є тиреоїдний гормональний статус. Вплив гормонів щитоподібної залози на швидкість та особливості загоєння бойових травм не вивчались, що й обумовлює актуальність цього дослідження. Мета дослідження. визначення основних закономірностей між об’ємом ранового ушкодження та змінами рівнів гормонів щитоподібної залози у сироватці крові на різних етапах ранової хвороби. Матеріали та методи. У досліджені брали участь 30 чоловіків, які отримали поранення м’яких тканин різного об’єму ураження. Вік поранених – 34,2+ 4,3 роки. Середня маса тіла становила 78 ±3,5 кг. Визначались рівні вільного Т3, вільного Т4 та ТТГ. Результати. У всіх обстежених осіб рівень вільного Т3 не зазнав статистично значущих змін впродовж усього терміну дослідження у порівнянні із його рівнем у термін на 1-3 добу і знаходився в діапазоні 3,4-5,2 пмоль/л. У осіб із пораненнями легкого та середнього ступеня важкості рівні вільного Т4 не відрізнялись. Рівні вільного Т4 у осіб із важким пораненням були вірогідно (р<0,05) вищими на усіх етапах дослідження у порівнянні із особами з середнім та легким пораненням. Рівень ТТГ при пораненнях середнього та важкого ступеня зростав (р<0,05) у порівнянні із легкими пораненнями у термін 1-5 день. Але на 14 добу дослідження значення даного показника вірогідно зменшувалося (р<0,05) у обох групах до рівня, однакового із групою осіб, які зазнали поранення легкого ступеня. Висновки. У обстежених осіб із пораненням важкого та середнього ступеня мало місце вірогідне зростання рівнів ТТГ у термін 1 - 5 доби від поранення, яке супроводжувалось також зростанням рівня вільного Т4. Рівні Т3 вірогідних змін не зазнали.
- 14 March 2024
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 81 (1) , 35-40
Open AccessЗМІНИ В ТИРЕОЇДНОМУ ГОРМОНАЛЬНОМУ СТАТУСІ ПОРАНЕНИХ В ЗАЛЕЖНОСТІ ВІД ОБ’ЄМУ РАНОВОГО УШКОДЖЕННЯ
Рановий процес – це складний комплекс місцевих та загальних реакцій організму, що розвиваються у відповідь на пошкодження тканин. Внаслідок розпочатої у лютому 2022 року збройної агресії росії проти України значно зросла кількість осіб, які отримали бойову травму. Швидкість загоєння цих травм та перебіг ранового процесу залежать від багатьох факторів, одним з яких є тиреоїдний гормональний статус. Вплив гормонів щитоподібної залози на швидкість та особливості загоєння бойових травм не вивчались, що й обумовлює актуальність цього дослідження. Мета дослідження. визначення основних закономірностей між об’ємом ранового ушкодження та змінами рівнів гормонів щитоподібної залози у сироватці крові на різних етапах ранової хвороби. Матеріали та методи. У досліджені брали участь 30 чоловіків, які отримали поранення м’яких тканин різного об’єму ураження. Вік поранених – 34,2+ 4,3 роки. Середня маса тіла становила 78 ±3,5 кг. Визначались рівні вільного Т3, вільного Т4 та ТТГ. Результати. У всіх обстежених осіб рівень вільного Т3 не зазнав статистично значущих змін впродовж усього терміну дослідження у порівнянні із його рівнем у термін на 1-3 добу і знаходився в діапазоні 3,4-5,2 пмоль/л. У осіб із пораненнями легкого та середнього ступеня важкості рівні вільного Т4 не відрізнялись. Рівні вільного Т4 у осіб із важким пораненням були вірогідно (р<0,05) вищими на усіх етапах дослідження у порівнянні із особами з середнім та легким пораненням. Рівень ТТГ при пораненнях середнього та важкого ступеня зростав (р<0,05) у порівнянні із легкими пораненнями у термін 1-5 день. Але на 14 добу дослідження значення даного показника вірогідно зменшувалося (р<0,05) у обох групах до рівня, однакового із групою осіб, які зазнали поранення легкого ступеня. Висновки. У обстежених осіб із пораненням важкого та середнього ступеня мало місце вірогідне зростання рівнів ТТГ у термін 1 - 5 доби від поранення, яке супроводжувалось також зростанням рівня вільного Т4. Рівні Т3 вірогідних змін не зазнали.
- Open Access
- 3 March 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (1) , 53-57
Relationship between hyperleptinemia and cardiometabolic risk in persons with obesity
Background. Obesity remains a global social and medical problem today. The results of recent research demonstrate the presence of overweight in 30–70 % and obesity in 10–30 % of adults, while the prevalence of obesity is increasing at an alarming rate in both economically developed and developing countries of the world. In Ukraine, according to the World Health Organization, 41.2 % of men and 58.5 % of women are overweight or obese. Obesity is a risk factor for the development of a number of diseases — type 2 diabetes, hypertension, coronary heart disease, non-alcoholic fatty liver disease, gastroesophageal reflux disease, obstructive sleep apnea syndrome, etc. The presence of hyperleptinemia and weight loss resistance are common characteristics of obesity. The purpose of the study was to reveal the relationship between leptin levels and cardiometabolic risk in obese patients. Materials and methods. Fifty-three patients (43 women, 10 men) were examined. Body mass index was calculated as the ratio of body weight (kg) to height (m2). The classification criteria of the World Health Organization were used to diagnose overweight, obesity, and its degree. The level of leptin was assessed by an enzyme immunoassay on the ImmunnoChem-2000 device. The relationship between indicators was evaluated using the Spearman’s rank correlation coefficient. Results. Hyperleptinemia in obese patients is an indicator of low-grade inflammation. A significant increase in the serum leptin is noted in obese patients. Correlation analysis of waist circumference with leptin level in women and men demonstrated its importance both before and after treatment. A significant cardiometabolic risk was detected in the examined patients from the Ukrainian population. Against the background of a comprehensive treatment for six months, a decrease in body weight, waist circumference (p < 0.05) and in leptin level (p < 0.05) was noted in both women and men. Conclusions. The relationship was found between leptin level and cardiometabolic risk in obese patients.
- 3 March 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (1) , 53-57
Open AccessRelationship between hyperleptinemia and cardiometabolic risk in persons with obesity
Background. Obesity remains a global social and medical problem today. The results of recent research demonstrate the presence of overweight in 30–70 % and obesity in 10–30 % of adults, while the prevalence of obesity is increasing at an alarming rate in both economically developed and developing countries of the world. In Ukraine, according to the World Health Organization, 41.2 % of men and 58.5 % of women are overweight or obese. Obesity is a risk factor for the development of a number of diseases — type 2 diabetes, hypertension, coronary heart disease, non-alcoholic fatty liver disease, gastroesophageal reflux disease, obstructive sleep apnea syndrome, etc. The presence of hyperleptinemia and weight loss resistance are common characteristics of obesity. The purpose of the study was to reveal the relationship between leptin levels and cardiometabolic risk in obese patients. Materials and methods. Fifty-three patients (43 women, 10 men) were examined. Body mass index was calculated as the ratio of body weight (kg) to height (m2). The classification criteria of the World Health Organization were used to diagnose overweight, obesity, and its degree. The level of leptin was assessed by an enzyme immunoassay on the ImmunnoChem-2000 device. The relationship between indicators was evaluated using the Spearman’s rank correlation coefficient. Results. Hyperleptinemia in obese patients is an indicator of low-grade inflammation. A significant increase in the serum leptin is noted in obese patients. Correlation analysis of waist circumference with leptin level in women and men demonstrated its importance both before and after treatment. A significant cardiometabolic risk was detected in the examined patients from the Ukrainian population. Against the background of a comprehensive treatment for six months, a decrease in body weight, waist circumference (p < 0.05) and in leptin level (p < 0.05) was noted in both women and men. Conclusions. The relationship was found between leptin level and cardiometabolic risk in obese patients.